Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for CMV prevention in Chinese HSCT recipients
NCT05763823Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of letermovir in cytomegalovirus infection (CMV), sponsored by Merck & Co.. Started Mar 2023; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05763823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05763823.